Benitec Biopharma Inc.
BNTC
$13.59
-$0.305-2.20%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 1.81% | -2.12% | -11.19% | -8.63% | -15.73% |
| Total Depreciation and Amortization | 4.13% | -2.49% | -9.97% | -6.67% | -11.02% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 226.42% | 375.71% | 82.64% | 1.21% | -37.64% |
| Change in Net Operating Assets | -164.52% | -106.53% | 64.43% | 91.15% | 1,043.44% |
| Cash from Operations | -20.39% | -4.68% | -7.72% | -7.63% | 0.55% |
| Capital Expenditure | -19,000.00% | -17,800.00% | -17,800.00% | -1,284.62% | 92.31% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -19,000.00% | -17,800.00% | -17,800.00% | -1,284.62% | 92.31% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 166.89% | 109.48% | 313.34% | 72.90% | 72.90% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 1.15% | 1.21% | -215.25% | -58.59% | -58.59% |
| Cash from Financing | 184.71% | 121.23% | 324.78% | 74.57% | 74.57% |
| Foreign Exchange rate Adjustments | 655.56% | -231.82% | -101.94% | -97.39% | -114.59% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 489.17% | 350.46% | 3,154.16% | 464.95% | 648.63% |